In a nutshell This phase 1/2 trial will investigate the safety and effectiveness of APL-101 in advanced non-small cell lung cancer (NSCLC). The main outcomes will be to determine the recommended phase 2 dose (RP2D) and the response rate (RR) in phase 2. This trial is recruiting at multiple locations across the US. The details...
Read MoreCurrent stage-Stage III Posts on Medivizor
MRI prognostic parameters in tailoring treatment for locally advanced rectal cancer
In a nutshell This study investigated the use of MRI predictive results to decide the best treatment for patients with locally advanced rectal cancer (LARC). Researchers suggested that early MRI results should be used in the treatment decision making. Some background Colorectal cancer is the third most common cancer in the world. Patients with LARC...
Read MoreLooking for patients with advanced melanoma to test a combination of antibody and enzyme drugs
In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...
Read MoreSearching for patients with advanced colorectal cancer to test a new combination therapy
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In many...
Read MoreSearching for patients with advanced triple-negative breast cancer to test a new combination treatment
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read MoreLooking for patients with BRAF positive inoperable colorectal cancer to test a new treatment combination
In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...
Read MoreWaiting at least 8 weeks for surgery after chemoradiotherapy increases rectal cancer response
In a nutshell This study investigated the best interval time between chemoradiation therapy and rectal cancer surgery for the best outcomes in patients with rectal cancer. Researchers suggested that waiting at least 8 weeks until the surgery increases the tumor response to the treatment. Some background The standard treatment for locally advanced...
Read MoreLooking for participants with advanced cancer to test a new therapy
In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...
Read MoreSearching for patients with advanced solid tumors to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced solid tumors. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details The treatment options for advanced cancer are limited. New drugs are...
Read MoreSearching for patients with melanoma to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read MoreSearching for patients with melanoma to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read MoreDurvalumab as third-line treatment in advanced lung cancer – does gene expression affect response?
In a nutshell This study investigated if durvalumab (Infinzi) is effective in advanced non-small cell lung cancer (NSCLC) that has progressed on previous therapies. They found that the response to durvalumab was greatest in patients with high PD-L1 expression. Some background Non-small cell lung cancer (NSCLC) is the most common form...
Read More
